$95,220.03 research Payment -- Merck & Co to Dr. Catherine Morris

Pulmonologist Catherine Morris Receives Over $95,000 Research Payment from Merck for Trikafta

This page provides a detailed analysis of a $95,220.03 research payment from Merck & Co to Dr. Catherine Morris. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$95,220.03
Payment Typeresearch
Payment NatureResearch
Pharmaceutical CompanyMerck & Co
PhysicianDr. Catherine Morris
NPI Number1345266982
Physician SpecialtyPulmonology
LocationJacksonville, FL
Date of Payment2024-11-12
Related Drug/DeviceTrikafta
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Merck & Co made a $95.2K research payment to Catherine Morris, a Pulmonology specialist in Jacksonville, FL. The payment was associated with Trikafta. Catherine Morris received a substantial research payment of $95,220.03 from Merck & Co. The payment is associated with research related to Trikafta, a drug used in Pulmonology. This payment represents a significant financial engagement between a pharmaceutical company and a healthcare provider in the Pulmonology specialty.

Patient Guidance: What This Payment Means for You

This payment is for research purposes and may contribute to the development of new treatments. It does not represent a direct payment for your personal medical care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Research payments of this magnitude are not uncommon for clinical trials or significant research studies within the Pulmonology specialty, especially for novel or complex treatments.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $95.2K payment for?

This was a research payment of $95.2K from Merck & Co to Catherine Morris, categorized as "Research". It was associated with Trikafta. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Catherine Morris accept pharmaceutical money?

Yes, Catherine Morris received this $95.2K payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Catherine Morris's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $95.2K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Pulmonology?

To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Catherine Morris's relationship with Merck & Co?

The payment amount is notably high for a single research payment. This $95.2K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Pulmonology?

The payment is specifically designated for research activities.

What should patients do after learning about this payment?

This payment is for research purposes and may contribute to the development of new treatments. It does not represent a direct payment for your personal medical care.

What else should I know about this research payment?

The recipient's specialty is Pulmonology, and the drug mentioned is Trikafta.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.